false 0000727510 0000727510 2024-07-02 2024-07-02 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

 

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

 

FORM 8-K/A

(Amendment No. 1)

 

CURRENT REPORT

 

Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

 

Date of Report (Date of earliest event reported): July 2, 2024

 

ENZON PHARMACEUTICALS, INC.

(Exact name of registrant as specified in its charter)

 

Delaware

(State or other jurisdiction
of incorporation)

  

001-36435

(Commission File Number)

  

22-2372868

(IRS Employer Identification No.)

 

20 Commerce Drive (Suite 135), Cranford, New Jersey

(Address of principal executive offices)

  

07016

(Zip Code)

 

(732) 980-4500

(Registrant’s telephone number, including area code)

 

Not Applicable

(Former name or former address, if changed since last report)

 

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

 

¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

 

¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

 

¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

 

¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 

Securities registered pursuant to Section 12(b) of the Act:

 

Title of each class   Trading Symbol(s)   Name of each exchange on which registered
None   N/A   N/A

 

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

 

Emerging growth company  ¨

 

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.  ¨

 

 

 

 

 

EXPLANATORY NOTE

 

On July 2, 2024, Enzon Pharmaceuticals, Inc. (the “Company”) filed a Current Report on Form 8-K in connection with the Company’s 2024 Annual Meeting of Stockholders (the “Annual Meeting”) and a notice regarding deadlines for any stockholder proposals pursuant to Rule 14a-8 under the Securities Exchange Act of 1934, as amended (the “Exchange Act”). This amendment is being filed solely to clarify the record date previously disclosed and all other information herein remains unchanged.

 

Item 5.08Shareholder Director Nominations.

 

The Board of Directors (the “Board”) of the Company has established September 26, 2024, as the date for the Company’s Annual Meeting. The Board also established August 7, 2024, as the record date for the Annual Meeting. Due to the fact that the Company is now holding its Annual Meeting more than 25 days from June 8, 2024, the Company is providing the due date for submission of any qualified stockholder proposal or director nominations.

 

In accordance with Rule 14a-5(f) and Rule 14a-8(e) under the Exchange Act, and the Company’s bylaws (the “Bylaws”), the deadline for receipt of stockholder proposals or nominations for inclusion in the Company’s proxy statement for the Annual Meeting pursuant to Rule 14a-8 will be no later than July 12, 2024 and must be received by the Company’s secretary at 20 Commerce Drive, Suite 135, Cranford, New Jersey, 07016 no later than such date. Stockholder proposals must comply with all of the applicable requirements set forth in the rules and regulations of the Securities and Exchange Commission, including Rule 14a-8 under the Exchange Act and the Bylaws.

 

 

 

 

SIGNATURES

 

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

 

  ENZON PHARMACEUTICALS, INC.
  (Registrant)
Date: July 11, 2024    
  By: /s/ Richard L. Feinstein
  Name: Richard L. Feinstein
  Title: Chief Executive Officer, Chief Financial Officer and Secretary

 

 

v3.24.2
Cover
Jul. 02, 2024
Cover [Abstract]  
Document Type 8-K/A
Amendment Flag false
Document Period End Date Jul. 02, 2024
Entity File Number 001-36435
Entity Registrant Name ENZON PHARMACEUTICALS, INC.
Entity Central Index Key 0000727510
Entity Tax Identification Number 22-2372868
Entity Incorporation, State or Country Code DE
Entity Address, Address Line One 20 Commerce Drive (Suite 135)
Entity Address, City or Town Cranford
Entity Address, State or Province NJ
Entity Address, Postal Zip Code 07016
City Area Code 732
Local Phone Number 980-4500
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Entity Emerging Growth Company false
Enzon (QX) (USOTC:ENZN)
Historical Stock Chart
From Nov 2024 to Dec 2024 Click Here for more Enzon (QX) Charts.
Enzon (QX) (USOTC:ENZN)
Historical Stock Chart
From Dec 2023 to Dec 2024 Click Here for more Enzon (QX) Charts.